Hospital-acquired and Ventilator-Associated Pneumonia

Publication Date: July 14, 2016

Key Points

Key Points

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) continue to be frequent complications of hospital care. Together, they are among the most common hospital-acquired infections (HAIs), accounting for 22% of all HAIs in a multistate point-prevalence survey.

All-cause mortality associated with VAP has been reported to range from 20%–50%.

Serious complications from HAP occur in approximately 50% of patients.

Diagnosis

...gnosis...

...isk Factors for Multidrug-Resistant PathogensHav...


...obiologic Methods...

...and IDSA suggest noninvasive sampling with semiq...

...ampling with semiquantitative cultur...

...nd IDSA suggest that patients with susp...


Biomarkers

...patients with suspected HAP/VAP, ATS a...

...patients with suspected HAP/VAP, ATS and...

...or patients with suspected HAP/VAP, ATS an...

...ith suspected HAP/VAP, ATS and IDSA...


Treatment

...atment...

...nitial

...ventilator-associated tracheobronchitis (VAT) ATS...

...nd IDSA recommend that all hospital...

...d IDSA recommend that empiric treatment reg...

...h suspected VAP, ATS and IDSA recommend incl...

...nd IDSA suggest including an agent active against...

...DSA suggest including an agent acti...

...iric coverage for MRSA is indicated, AT...

...empiric treatment that includes coverage for...

...TS and IDSA suggest prescribing two anti...

...and IDSA suggest prescribing one antibio...

In patients with suspected VAP, ATS and IDSA sug...

In patients with suspected VAP, ATS and...

...IDSA recommend that empiric antibi...

...commend that all hospitals regular...

...ing treated empirically for HAP, ATS and IDSA r...

...or patients with HAP who are being treated empiri...

...or patients with HAP who require empiri...

...ients with HAP who are being treated empirica...

...th HAP who are being treated empirically, AT...

...ents with HAP who are being treated empirica...

...with HAP who are being treated empiri...


...mization

...or patients with HAP/VAP, ATS and IDSA suggest...


...aled Antibiotic...

...r patients with VAP due to Gram-negative bacilli...


...thogen-Specific The...

...DSA recommend that MRSAHAP/VAP be treated with ei...

...s with HAP/VAP due to P. aeruginosa,...

...ith HAP/VAP due to P. aeruginosa, ATS a...

...atients with HAP/VAP due to P. aeruginos...

...or patients with HAP/VAP due to P. aerugi...

...patients with HAP/VAP due to P. aeruginosa, ATS an...

...h HAP/VAP due to extended-spectrum ...

...n patients with HAP/VAP caused by Acinetobacter s...

...n patients with HAP/VAP caused by Acinetobacte...

...suggest adjunctive inhaled colistin. ( W , L)705...

...nts with HAP/VAP caused by Acinetobacter s...

...ients with HAP/VAP caused by Acinetobacter s...

...ith HAP/VAP caused by a carbapenem-resistant...

...nd IDSA suggest adjunctive inhaled colisti...

...ents with VAP, ATS and IDSA recommend...

...ts with HAP, ATS and IDSA recommend...

...s with HAP/VAP, ATS and IDSA suggest th...

...patients with HAP/VAP, ATS and IDSA suggest us...

...patients with suspected HAP/VAP, ATS and IDSA su...

...ommended Initial Empiric Antibiotic Therapy for...

...ble 3. Empiric Treatment Options for Suspected M...